Personalizing the approach to asthma treatment

ABSTRACT

Introduction: Personalized/precision medicine has changed the vision of respiratory diseases. Asthma is now recognized as a heterogeneous disease with different pathogenic mechanisms, clinical course, and different responses to different treatments.

Areas covered: According to this vision, the prescription of treatments has become more tailored. Taking into account the clinical and molecular phenotypes and endotypes, the focus has moved to the predominant characteristics of the inflammatory process, the clinical aspects, and the study of the biological mechanisms. Eventually, researchers highlighted the presence and the etiological dignity of treatable traits defined as therapeutic targets identified by specific phenotypes or endotypes through validated biomarkers.

Expert commentary: All these aspects involve a novel approach, with a ‘point-of-care’ assessment, that seems to be more and more central to warrant a forward-step to the personalization of asthma treatment. The availability of portable, hand-held devices to assess specific biomarkers, represents an additional advantage.

KEYWORDS:

• Personalized medicine
• asthma treatment
• biologics

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper has been partially supported by ARMIA (Associazione Ricerca Malattie Immunologiche e Allergiche) Genova.